Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Osteoporosis

  Free Subscription


Articles published in J Clin Endocrinol Metab

Retrieve available abstracts of 66 articles:
HTML format
Text format



Single Articles


    May 2017
  1. OHLSSON C, Sundh D, Wallerek A, Nilsson M, et al
    Response to Letter: "Cortical Bone Area Predicts Incident Fractures Independently of Areal Bone Mineral Density in Older Men".
    J Clin Endocrinol Metab. 2017;102:1782.
    PubMed     Text format    


  2. ZHANG Y, Xiao H, Sheng ZF
    Letter to the Editor: "Cortical Bone Area Predicts Incident Fractures Independently of Areal Bone Mineral Density in Older Men".
    J Clin Endocrinol Metab. 2017;102:1780-1781.
    PubMed     Text format    


    April 2017
  3. GONZALEZ RODRIGUEZ E, Lamy O, Stoll D, Metzger M, et al
    High evening cortisol level is associated with low TBS and increased prevalent vertebral fractures. OsteoLaus study.
    J Clin Endocrinol Metab. 2017 Apr 4. doi: 10.1210/jc.2016-3804.
    PubMed     Text format     Abstract available


  4. WESSELING-PERRY K, Makitie RE, Valimaki VV, Laine T, et al
    Osteocyte protein expression is altered in low-turnover osteoporosis caused by mutations in WNT1 and PLS3.
    J Clin Endocrinol Metab. 2017 Apr 3. doi: 10.1210/jc.2017-00099.
    PubMed     Text format     Abstract available


    March 2017
  5. VALDERRABANO RJ, Lee J, Lui LY, Hoffman AR, et al
    Older Men with Anemia Have Increased Fracture Risk Independent of Bone Mineral Density.
    J Clin Endocrinol Metab. 2017 Mar 20. doi: 10.1210/jc.2017-00266.
    PubMed     Text format     Abstract available


  6. WANG Y, Wactawski-Wende J, Sucheston-Campbell LE, Preus L, et al
    Gene-hormone therapy interaction and fracture risk in postmenopausal women.
    J Clin Endocrinol Metab. 2017 Mar 6. doi: 10.1210/jc.2016-2936.
    PubMed     Text format     Abstract available


  7. BURR DB, Lane JE, Howe TS, Ng AC, et al
    Response to PD Miller, Underdiagnosis and Undertreatment of Osteoporosis: The Battle To Be Won.
    J Clin Endocrinol Metab. 2017;102:1088-1089.
    PubMed     Text format    


  8. TROVAS G
    Letter to the Editor: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Nine Clinical Cases Report.
    J Clin Endocrinol Metab. 2017;102:1086.
    PubMed     Text format    


    February 2017
  9. NOTSU M, Yamauchi M, Yamamoto M, Nawata K, et al
    Primary aldosteronism as a risk factor for vertebral fracture.
    J Clin Endocrinol Metab. 2017 Feb 9. doi: 10.1210/jc.2016-3206.
    PubMed     Text format    


    January 2017
  10. VUORIMIES I, Mayranpaa MK, Valta H, Kroger H, et al
    Bisphosphonate Treatment and the Characteristics of Femoral Fractures in Children with Osteogenesis Imperfecta.
    J Clin Endocrinol Metab. 2017 Jan 17. doi: 10.1210/jc.2016-3745.
    PubMed     Text format     Abstract available


    November 2016
  11. OHLSSON C, Sundh D, Wallerek A, Nilsson M, et al
    Cortical bone area predicts incident fractures independently of areal bone mineral density in older men.
    J Clin Endocrinol Metab. 2016 Nov 22:jc20163177.
    PubMed     Text format     Abstract available


  12. CHAWLA H, Saha S, Kandaswamy D, Sharma R, et al
    Vertebral fractures and bone mineral density in patients with idiopathic hypoparathyroidism on long term follow-up.
    J Clin Endocrinol Metab. 2016 Nov 4:jc20163292.
    PubMed     Text format     Abstract available


    October 2016
  13. VALIMAKI VV, Makitie O, Pereira R, Laine C, et al
    Teriparatide Treatment in Patients with WNT1 or PLS3 Mutation-Related Early-Onset Osteoporosis - A Pilot Study.
    J Clin Endocrinol Metab. 2016 Oct 12:jc20162423.
    PubMed     Text format     Abstract available


  14. LAMY O, Gonzalez-Rodriguez E, Stoll D, Hans D, et al
    Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report.
    J Clin Endocrinol Metab. 2016 Oct 12:jc20163170.
    PubMed     Text format     Abstract available


    September 2016
  15. ESCHE J, Johner S, Shi L, Schonau E, et al
    Urinary citrate, an index of acid-base status, predicts bone strength in youths and fracture risk in adult females.
    J Clin Endocrinol Metab. 2016 Sep 27:jc20162677.
    PubMed     Text format     Abstract available


  16. MAJUMDAR SR, Leslie WD, Lix LM, Morin SN, et al
    Longer Duration of Diabetes Strongly Impacts Fracture Risk Assessment: The Manitoba BMD Cohort.
    J Clin Endocrinol Metab. 2016 Sep 7:jc20162569.
    PubMed     Text format     Abstract available


  17. MILLER PD, Pannacciulli N, Wagman RB, Cummings SR, et al
    Response to the Letter: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid.
    J Clin Endocrinol Metab. 2016;101:L91-2.
    PubMed     Text format    


  18. MAKRAS P, Polyzos SA, Anastasilakis AD
    Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid.
    J Clin Endocrinol Metab. 2016;101:L89-90.
    PubMed     Text format    


    August 2016
  19. KOCIJAN R, Muschitz C, Geiger E, Skalicky S, et al
    Circulating microRNA signatures in patients with idiopathic and postmenopausal osteoporosis and fragility fractures.
    J Clin Endocrinol Metab. 2016 Aug 23:jc20162365.
    PubMed     Text format     Abstract available


  20. WAGENKNECHT LE, Divers J, Register TC, Russell GB, et al
    Bone mineral density and progression of subclinical atherosclerosis in African Americans with type 2 diabetes.
    J Clin Endocrinol Metab. 2016 Aug 23:jc20161934.
    PubMed     Text format     Abstract available


  21. SUGIYAMA T, Oda H
    Letter to the Editor: Combination Treatment With Teriparatide and Denosumab in Osteoporosis.
    J Clin Endocrinol Metab. 2016;101:L80-1.
    PubMed     Text format    


    June 2016
  22. CARTWRIGHT B, Robinson J, Seed PT, Fogelman I, et al
    Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: a randomised controlled trial of the effects on bone mineral density.
    J Clin Endocrinol Metab. 2016 Jun 24:jc20154063.
    PubMed     Text format     Abstract available


  23. CHANG PY, Gold EB, Cauley JA, Johnson WO, et al
    Triglyceride Levels and Fracture Risk in Midlife Women: Study of Women's Health Across the Nation (SWAN).
    J Clin Endocrinol Metab. 2016 Jun 13:jc20161366.
    PubMed     Text format     Abstract available


  24. MILLER PD, Pannacciulli N, Brown JP, Czerwinski E, et al
    Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.
    J Clin Endocrinol Metab. 2016 Jun 6:jc20161801.
    PubMed     Text format     Abstract available


    May 2016
  25. AFSHINNIA F, Pennathur S
    Association of Hypoalbuminemia with Osteoporosis: Analysis of the National Health and Nutrition Examination Survey.
    J Clin Endocrinol Metab. 2016 May 4:jc20161099.
    PubMed     Text format     Abstract available


  26. MORELLI V, Eller-Vainicher C, Palmieri S, Cairoli E, et al
    Prediction of vertebral fractures in patients with monolateral adrenal incidentalomas.
    J Clin Endocrinol Metab. 2016 May 4:jc20161423.
    PubMed     Text format     Abstract available


  27. SUGIYAMA T, Kim YT, Oda H
    Letter to the Editor: Strontium Ranelate in the Treatment of Osteoporosis: A Possible Mechanism.
    J Clin Endocrinol Metab. 2016;101:L64-5.
    PubMed     Text format    


  28. AMREIN K, Perl S, Dimai HP
    Letter to the Editor: Preadmission Bisphosphonate and Mortality in Critically Ill Patients.
    J Clin Endocrinol Metab. 2016;101:L60-1.
    PubMed     Text format    


    March 2016
  29. MAJUMDAR SR, Josse RG, Lin M, Eurich DT, et al
    Does Sitagliptin Affect the Rate of Osteoporotic Fractures in Type-2 Diabetes? Population-Based Cohort Study.
    J Clin Endocrinol Metab. 2016 Mar 1:jc20154180.
    PubMed     Text format     Abstract available


  30. MILLER PD
    Underdiagnoses and Undertreatment of Osteoporosis: The Battle to Be Won.
    J Clin Endocrinol Metab. 2016;101:852-859.
    PubMed     Text format     Abstract available


  31. KRONENBERG HM
    Bone and Mineral Metabolism: Where Are We, Where Are We Going, and How Will We Get There?
    J Clin Endocrinol Metab. 2016;101:795-8.
    PubMed     Text format     Abstract available


    February 2016
  32. UPALA S, Sanguankeo A
    Association Between Hyponatremia, Osteoporosis and Fracture: a Systematic Review and Meta-analysis.
    J Clin Endocrinol Metab. 2016 Feb 25:jc20154228.
    PubMed     Text format     Abstract available


  33. CARBONE L, Johnson KC, Huang Y, Pettinger M, et al
    Sodium Intake and Osteoporosis. Findings from the Women's Health Initiative.
    J Clin Endocrinol Metab. 2016 Feb 10:jc20154017.
    PubMed     Text format     Abstract available


  34. DEMPSTER DW, Zhou H, Recker RR, Brown JP, et al
    Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.
    J Clin Endocrinol Metab. 2016 Feb 9:jc20154181.
    PubMed     Text format     Abstract available


    January 2016
  35. LEE P, Ng C, Slattery A, Nair P, et al
    Preadmission bisphosphonate and mortality in critically ill patients.
    J Clin Endocrinol Metab. 2016 Jan 18:jc20153467.
    PubMed     Text format     Abstract available


  36. LEE SH, Cho EH, Ahn SH, Kim HM, et al
    Prediction of Future Osteoporotic Fracture Occurrence by Genetic Profiling: A 6-year Follow-up Observational Study.
    J Clin Endocrinol Metab. 2016 Jan 12:jc20153972.
    PubMed     Text format     Abstract available


  37. TABATABAI LS, Bloom J, Stewart S, Sellmeyer DE, et al
    FSH Levels Predict Bone Loss in Premenopausal Women Treated for Breast Cancer More Than One Year After Treatment.
    J Clin Endocrinol Metab. 2016 Jan 12:jc20153149.
    PubMed     Text format     Abstract available


  38. MARTIN BR, McCabe GP, McCabe L, Jackson GS, et al
    Effect of Hesperidin with and without a Calcium (Calcilock(R)) Supplement on Bone Health in Postmenopausal Women.
    J Clin Endocrinol Metab. 2016 Jan 11:jc20153767.
    PubMed     Text format     Abstract available


  39. WALKER MD, Nishiyama KK, Zhou B, Cong E, et al
    Effect of Low Vitamin D on Volumetric Bone Mineral Density, Bone Microarchitecture and Stiffness in Primary Hyperparathyroidism.
    J Clin Endocrinol Metab. 2016 Jan 8:jc20154218.
    PubMed     Text format     Abstract available


    December 2015
  40. MUKA T, de Jonge EA, Kiefte-de Jong JC, Uitterlinden AG, et al
    The influence of serum uric acid on bone mineral density, hip geometry and fracture risk: The Rotterdam Study.
    J Clin Endocrinol Metab. 2015 Dec 18:jc20152446.
    PubMed     Text format     Abstract available


  41. KIZILGUL M, Sencar E, Ucan B, Ozbek M, et al
    Letter to the Editor: Possible Decrease in GIP Levels May Explain Increased Plasma Dipeptidyl Peptidase-4 Activity-Associated Osteoporosis.
    J Clin Endocrinol Metab. 2015;100:L128-9.
    PubMed     Text format    


    November 2015
  42. AFSHINNIA F, Wong KK, Sundaram B, Ackermann RJ, et al
    Hypoalbuminemia and Osteoporosis: Reappraisal of a Controversy.
    J Clin Endocrinol Metab. 2015 Nov 24:jc20153212.
    PubMed     Text format     Abstract available


  43. WATTS NB, Bilezikian JP, Usiskin K, Edwards R, et al
    Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
    J Clin Endocrinol Metab. 2015 Nov 18:jc20153167.
    PubMed     Text format     Abstract available


  44. BILEZIKIAN JP, Watts NB, Usiskin K, Polidori D, et al
    Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.
    J Clin Endocrinol Metab. 2015 Nov 18:jc20151860.
    PubMed     Text format     Abstract available


  45. SALVATORI R
    Letter to the Editor: Comment on "Effect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Study" by Kratz E., et al.
    J Clin Endocrinol Metab. 2015;100:L107.
    PubMed     Text format    


  46. KRANTZ E, Trimpou P, Landin-Wilhelmsen K
    Response to the Letter by Salvatori R.
    J Clin Endocrinol Metab. 2015;100:L108.
    PubMed     Text format    


  47. VAN VARSSEVELD NC, Sohl E, Drent ML, Lips P, et al
    Gender-Specific Associations of Serum Insulin-Like Growth Factor-1 With Bone Health and Fractures in Older Persons.
    J Clin Endocrinol Metab. 2015;100:4272-81.
    PubMed     Text format     Abstract available


  48. GEORGE S, Weber DR, Kaplan P, Hummel K, et al
    Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.
    J Clin Endocrinol Metab. 2015;100:4163-71.
    PubMed     Text format     Abstract available


    October 2015
  49. CHAVASSIEUX P, Portero-Muzy N, Paul Roux J, Garnero P, et al
    Are Biochemical Markers of Bone Turnover Representative of Bone Histomorphometry in 370 Postmenopausal Women?
    J Clin Endocrinol Metab. 2015 Oct 27:jc20152957.
    PubMed     Text format     Abstract available


  50. KIZILGUL M, Ozcelik O, Apaydin M, Ozbek M, et al
    Letter to the Editor: Possible Mechanisms of Hyponatremia-Induced Osteoporosis.
    J Clin Endocrinol Metab. 2015;100:L89-90.
    PubMed     Text format    


  51. CONTE C, Cecere A, Guglielmi G, Napoli N, et al
    Letter to the Editor: "GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women" by Iepsen E.W., et al.
    J Clin Endocrinol Metab. 2015;100:L92-3.
    PubMed     Text format    


  52. VERBALIS J
    Response to the Letter to the Editor.
    J Clin Endocrinol Metab. 2015;100:L91.
    PubMed     Text format    


  53. PACCOU J, Hardouin P, Cotten A, Penel G, et al
    The Role of Bone Marrow Fat in Skeletal Health: Usefulness and Perspectives for Clinicians.
    J Clin Endocrinol Metab. 2015;100:3613-21.
    PubMed     Text format     Abstract available


    September 2015
  54. CRANDALL CJ, Hovey KM, Andrews CA, Cauley JA, et al
    Bone Mineral Density as a Predictor of Subsequent Wrist Fractures: Findings from the Women's Health Initiative Study.
    J Clin Endocrinol Metab. 2015 Sep 14:jc20152568.
    PubMed     Text format     Abstract available


  55. COHEN A, Kamanda-Kosseh M, Recker RR, Lappe JM, et al
    Bone Density after Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis.
    J Clin Endocrinol Metab. 2015 Sep 10:jc20152829.
    PubMed     Text format     Abstract available


    August 2015
  56. TAN LJ, Wang ZE, Wu KH, Chen XD, et al
    Bivariate Genome-Wide Association Study Implicates ATP6V1G1 as a Novel Pleiotropic Locus Underlying Osteoporosis and Age at Menarche.
    J Clin Endocrinol Metab. 2015 Aug 27:jc20152095.
    PubMed     Text format     Abstract available


  57. KRANTZ E, Trimpou P, Landin-Wilhelmsen K
    Effect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Study.
    J Clin Endocrinol Metab. 2015 Aug 27:jc20151757.
    PubMed     Text format     Abstract available


  58. ZHENG T, Yang L, Liu Y, Liu H, et al
    Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of osteoporosis in postmenopausal women with normal glucose tolerance.
    J Clin Endocrinol Metab. 2015 Aug 10:jc20152233.
    PubMed     Text format     Abstract available


  59. BREITLING LP
    Liver enzymes and bone mineral density in the general population.
    J Clin Endocrinol Metab. 2015 Aug 4:jc20152016.
    PubMed     Text format     Abstract available


    July 2015
  60. CUMMINGS EA, Ma J, Fernandez CV, Halton J, et al
    Incident Vertebral Fractures in Children with Leukemia During the Four Years Following Diagnosis.
    J Clin Endocrinol Metab. 2015 Jul 14:JC20152176.
    PubMed     Text format     Abstract available


  61. ING SW, Orchard TS, Lu B, LaMonte MJ, et al
    TNF Receptors Predict Incident Hip Fracture Risk in the WHI Study and Fatty Acid Intake Does Not Modify this Association.
    J Clin Endocrinol Metab. 2015 Jul 10:JC20151662.
    PubMed     Text format     Abstract available


  62. TSAI JN, Zhu Y, Foley K, Lee H, et al
    Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate.
    J Clin Endocrinol Metab. 2015;100:2718-23.
    PubMed     Text format     Abstract available


    June 2015
  63. MIRIAM RACHEL USALA G, Fernandez SJ, Mete M, Cowen L, et al
    Hyponatremia is Associated with Increased Osteoporosis and Bone Fractures in a Large U. S. Health System Population.
    J Clin Endocrinol Metab. 2015 Jun 17:jc20151261.
    PubMed     Text format     Abstract available


  64. IEPSEN EW, Lundgren JR, Hartmann B, Pedersen O, et al
    GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women.
    J Clin Endocrinol Metab. 2015 Jun 4:jc20151176.
    PubMed     Text format     Abstract available


    May 2015
  65. COSMAN F, Nieves JW, Zion M, Garrett P, et al
    Daily or Cyclical Teriparatide Treatment in Women with Osteoporosis on no Prior Therapy and Women on Alendronate.
    J Clin Endocrinol Metab. 2015 May 11:jc20151715.
    PubMed     Text format     Abstract available


  66. CHEN CL, Chen NC, Liang HL, Hsu CY, et al
    Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients with Low Bone Mass.
    J Clin Endocrinol Metab. 2015 May 8:jc20151259.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Osteoporosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: